Harrow Health Inc stock (US4158581094): Ophthalmology player trades below analyst targets amid sector focus

Harrow Health Inc shares on Nasdaq continue to trade well under the average Wall Street price target, as the United States-based ophthalmic pharmaceuticals group expands its presence in eye-care therapies.

Harrow Health Inc, the United States-based ophthalmic pharmaceuticals group listed on Nasdaq under the ticker HROW, remains on the radar of equity investors as its share price continues to trade at a significant discount to the average analyst price target while the company focuses on prescription eye-care therapies.

According to Nasdaq data cited by Zacks, Harrow Health Inc last traded at about USD 30.77 on Nasdaq on 06/02/2026, with an after-hours indication of USD 30.83 as of 7:58 PM Eastern on the same day, highlighting the current market level for the stock in its home market.

Based on short-term price targets compiled by Zacks, the average price target for Harrow Health Inc stands at approximately USD 58.03 as of late May 2026, with individual analyst targets ranging from USD 52.20 on the low end to USD 65.00 on the high end, underlining a broad spread between the prevailing share price and sell-side expectations.

In the United States, Harrow Health Inc is positioned within the healthcare sector, and its primary focus on ophthalmology has drawn attention from investors looking at specialized pharmaceutical niches that address eye disorders and vision care.

Per a profile summary on Wallstreet Online updated in 2026, Harrow Health Inc is described as a pharmaceutical company concentrating on the discovery, development and commercialization of ophthalmic therapies, framing the business as a pure-play in the eye-care treatment segment rather than a diversified healthcare conglomerate.

The stock is also accessible to German investors through listings such as Tradegate, where Harrow Health Inc shares are quoted in euros and track the underlying Nasdaq line, providing an additional trading venue outside the company’s United States home exchange.

As of: 06/04/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: HROW
• Sector/industry: Ophthalmic pharmaceuticals
• Headquarters/country: Nashville, United States
• Core markets: United States ophthalmology practices, hospital and specialty eye-care channels
• Key revenue drivers: Commercial sales of branded ophthalmic products and related eye-care therapies
• Home exchange/listing venue: Nasdaq (HROW)
• Trading currency: USD

Harrow Health Inc: core business model

Harrow Health Inc operates as a focused ophthalmology company that develops and markets prescription eye-care products to ophthalmologists and optometrists, generating revenue mainly from sales of branded ophthalmic drugs and related therapies across the United States.

Industry trends and competitive position

The ophthalmic pharmaceuticals market in which Harrow Health Inc is active continues to benefit from structural trends such as an aging population, higher prevalence of eye diseases like cataracts and glaucoma, and increasing demand for minimally invasive procedures and specialty treatments, factors that support steady volumes for eye-care medicines over time.

Within this landscape, Harrow Health Inc positions itself as a specialist provider of ophthalmic therapies, competing with larger diversified pharmaceutical and eye-care companies while pursuing a focused pipeline and portfolio aimed specifically at the needs of eye surgeons and vision-care professionals.

Conclusion

Harrow Health Inc’s Nasdaq-listed shares currently trade around the low 30-dollar range, well below the average analyst price target compiled by Zacks, underscoring a notable valuation gap against sell-side expectations.

Against a backdrop of favorable structural trends in ophthalmic pharmaceuticals, the company’s specialized focus on eye-care therapies and its positioning in the United States healthcare market provide the central context for investors assessing the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.